JP2007518815A - 乳癌および原発性胆汁性肝硬変に関与するmmtv様ウイルスを阻害するためのアデホビルまたはテノホビルの使用 - Google Patents

乳癌および原発性胆汁性肝硬変に関与するmmtv様ウイルスを阻害するためのアデホビルまたはテノホビルの使用 Download PDF

Info

Publication number
JP2007518815A
JP2007518815A JP2006551327A JP2006551327A JP2007518815A JP 2007518815 A JP2007518815 A JP 2007518815A JP 2006551327 A JP2006551327 A JP 2006551327A JP 2006551327 A JP2006551327 A JP 2006551327A JP 2007518815 A JP2007518815 A JP 2007518815A
Authority
JP
Japan
Prior art keywords
adefovir
tenofovir
biliary cirrhosis
primary biliary
mmtv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006551327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007518815A5 (cg-RX-API-DMAC7.html
Inventor
トーマス チフラー,
ジャネット エル. ダグラス,
クレイグ エス. ギッブス,
Original Assignee
ギリアード サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ, インコーポレイテッド filed Critical ギリアード サイエンシーズ, インコーポレイテッド
Publication of JP2007518815A publication Critical patent/JP2007518815A/ja
Publication of JP2007518815A5 publication Critical patent/JP2007518815A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2006551327A 2004-01-21 2005-01-21 乳癌および原発性胆汁性肝硬変に関与するmmtv様ウイルスを阻害するためのアデホビルまたはテノホビルの使用 Pending JP2007518815A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
PCT/US2005/002043 WO2005072748A1 (en) 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Publications (2)

Publication Number Publication Date
JP2007518815A true JP2007518815A (ja) 2007-07-12
JP2007518815A5 JP2007518815A5 (cg-RX-API-DMAC7.html) 2008-03-13

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551327A Pending JP2007518815A (ja) 2004-01-21 2005-01-21 乳癌および原発性胆汁性肝硬変に関与するmmtv様ウイルスを阻害するためのアデホビルまたはテノホビルの使用

Country Status (10)

Country Link
US (2) US20070281911A1 (cg-RX-API-DMAC7.html)
EP (1) EP1732569B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007518815A (cg-RX-API-DMAC7.html)
AT (1) ATE445404T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005209256B2 (cg-RX-API-DMAC7.html)
CA (1) CA2553455A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005017131D1 (cg-RX-API-DMAC7.html)
ES (1) ES2334149T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ548532A (cg-RX-API-DMAC7.html)
WO (1) WO2005072748A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506837A (ja) * 2009-10-05 2013-02-28 アンバージェン, インコーポレイテッド 自己抗原を使用する原発性胆汁性肝硬変(pbc)を診断するための方法
JP2018522836A (ja) * 2015-06-01 2018-08-16 エクイガーミナル エスエー 抗ウイルス組成物
KR20200026156A (ko) * 2018-08-30 2020-03-10 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
JPWO2020171225A1 (ja) * 2019-02-22 2021-12-16 一素 村田 mTOR阻害剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
ATE534377T1 (de) 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
EP3993873A4 (en) * 2019-07-02 2023-09-20 Virago Vax Inc. SUPPRESSION OF BREAST TUMORS
CN119546620A (zh) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 用于治疗疾病的化合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512023A (ja) * 1999-06-01 2003-04-02 アルトン オケスナー メディカル ファウンデーション 原発性胆汁性肝硬変および自己免疫障害に関連する新規レトロウイルスの同定

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399204T1 (de) * 1999-06-30 2008-07-15 Univ Tulane Humanes endogenes retrovirus
HRP20030047B1 (hr) * 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512023A (ja) * 1999-06-01 2003-04-02 アルトン オケスナー メディカル ファウンデーション 原発性胆汁性肝硬変および自己免疫障害に関連する新規レトロウイルスの同定

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506837A (ja) * 2009-10-05 2013-02-28 アンバージェン, インコーポレイテッド 自己抗原を使用する原発性胆汁性肝硬変(pbc)を診断するための方法
JP2018522836A (ja) * 2015-06-01 2018-08-16 エクイガーミナル エスエー 抗ウイルス組成物
KR20200026156A (ko) * 2018-08-30 2020-03-10 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
JPWO2020171225A1 (ja) * 2019-02-22 2021-12-16 一素 村田 mTOR阻害剤
JP7663236B2 (ja) 2019-02-22 2025-04-16 一素 村田 mTOR阻害剤

Also Published As

Publication number Publication date
ATE445404T1 (de) 2009-10-15
CA2553455A1 (en) 2005-08-11
EP1732569B1 (en) 2009-10-14
US20050239753A1 (en) 2005-10-27
HK1099228A1 (en) 2007-08-10
AU2005209256B2 (en) 2010-11-18
AU2005209256A1 (en) 2005-08-11
EP1732569A1 (en) 2006-12-20
ES2334149T3 (es) 2010-03-05
WO2005072748A1 (en) 2005-08-11
US20070281911A1 (en) 2007-12-06
DE602005017131D1 (de) 2009-11-26
NZ548532A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
TWI905508B (zh) 用於治療病毒感染之方法
JP6616387B2 (ja) ホルボールエステルを含む組成物及びその使用法
AU2005209256B2 (en) Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis
AU2012275190B2 (en) Compositions, methods and kits for treating leukemia
US20120321637A1 (en) Combination cancer therapy with herv inhibition
TR201809518T4 (tr) Filoviridae virüs enfeksiyonlarının tedavisine yönelik yöntemler.
US20240043466A1 (en) Solid forms of a nucleoside analogue and uses thereof
US20250099476A1 (en) Solid forms of a nucleoside analogue and uses thereof
ES2356986T3 (es) Agentes antitumorales.
JP2020203947A (ja) Ns5a、ns5bまたはns3阻害剤を使用する、b型肝炎ウイルス感染症を処置するための方法
US20230158103A1 (en) Pld for use in combination in the treatment of coronavirus
ES2280259T3 (es) Complejos de galio de 3-hidroxi-4-pironas para tratar infecciones por procariotas intracelulares, virus de adn y retrovirus.
WO2007149382A2 (en) Therapeutic compositions and methods useful in treating hepatitis
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2025137446A1 (en) Solid forms of a nucleoside analogue and uses thereof
Morris-Natschke et al. Phospholipid analogs against HIV-1 infection and disease
US20070202079A1 (en) Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
CN106999596A (zh) 菜蓟滴定提取物及其用途
Sternfeld et al. Increased red cell corpuscular volume and hepatic mitochondrial function in NRTI-treated HIV infected patients
WO2007149381A2 (en) Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
HK1099228B (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
WO2016183276A1 (en) Immune modulation methods to reactivate hiv-1 reservoir
WO2022128810A1 (en) Materials and methods for treating viral and other medicinal conditions
US20080226596A1 (en) Therapeutic compositions and methods useful in treating hepatitis
US12544392B2 (en) Treatment of adenovirus infection or disease associated with adenovirus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111115